Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E20.08 EPS (ttm)5.71 Insider Own0.02% Shs Outstand2.77B Perf Week-0.03%
Market Cap317.37B Forward P/E16.06 EPS next Y7.13 Insider Trans-10.72% Shs Float2.73B Perf Month-3.91%
Income15.94B PEG3.09 EPS next Q1.57 Inst Own67.10% Short Float0.79% Perf Quarter-7.34%
Sales71.60B P/S4.43 EPS this Y-3.90% Inst Trans0.02% Short Ratio3.52 Perf Half Y3.26%
Book/sh26.47 P/B4.33 EPS next Y6.29% ROA- Target Price126.58 Perf Year17.63%
Cash/sh- P/C- EPS next 5Y6.50% ROE- 52W Range92.32 - 125.23 Perf YTD13.89%
Dividend3.20 P/FCF- EPS past 5Y2.80% ROI14.70% 52W High-8.52% Beta0.76
Dividend %2.79% Quick Ratio- Sales past 5Y2.60% Gross Margin69.60% 52W Low24.09% ATR1.38
Employees127100 Current Ratio- Sales Q/Q4.20% Oper. Margin26.10% RSI (14)37.92 Volatility1.02% 1.17%
OptionableYes Debt/Eq- EPS Q/Q28.20% Profit Margin22.30% Rel Volume1.04 Prev Close113.96
ShortableYes LT Debt/Eq- EarningsOct 18 BMO Payout39.80% Avg Volume6.14M Price114.56
Recom2.40 SMA20-2.30% SMA50-3.17% SMA2001.63% Volume6,400,515 Change0.53%
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Oct-26-16 01:04PM  Johnson & Johnson to Participate in the 25th Annual Credit Suisse Health Care Conference PR Newswire
11:46AM  Janssen Therapeutics receives funding from a special RFA
11:04AM  Xeljanz ER Is Driving Growth for Pfizer This Year
10:47AM  Biogen profit tops expectations; focus on CEO search, new drugs
08:54AM  Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales
08:45AM  Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More
08:05AM  Bristol-Myers Squibbs 3Q16 Estimates: Virology Segment
05:23AM  Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation
Oct-25-16 12:46PM  Why Did the Nutrition Segments Performance Fall?
11:13AM  4 Health Care Stock Picks for Your Long-Term Portfolio
11:04AM  Johnson & Johnsons Valuation Cheat Sheet 3Q16
10:04AM  Analyzing Future Estimates for Johnson & Johnson
08:04AM  Johnson & Johnsons Profitability and Financial Guidance
06:00AM  CNBC launches a new index to find hidden value in stocks at CNBC
Oct-24-16 04:20PM  Alkermes, Lundbeck Cannibalize Johnson & Johnson's Schizophrenia Sales
11:04AM  Major Developments for Johnson & Johnson in 3Q16
10:05AM  What Do Analysts Say about JNJ after Its 3Q16 Results?
10:04AM  JNJs Medical Devices Segment: How Did It Perform in 3Q16?
09:30AM  The Zacks Analyst Blog Highlights: McDonald's, Netflix, Goldman Sachs Group, Johnson & Johnson and Verizon Communications
08:28AM  Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More
08:05AM  Analyzing Johnson & Johnsons Recent Stock Performance
Oct-23-16 01:00PM  The Clinton Factor: 5 Stocks That Could Thrive if She Is Elected
Oct-21-16 06:04PM  JNJ Moved to Restructure Its Medical Devices Business in 3Q16
05:25PM  Dow 30 Stock Roundup: AmEx, Goldman, IBM Earnings Impress; Travelers, Verizon Disappoint
05:04PM  Medical Devices Revive JNJs Revenue Performance
02:55PM  Highlights from Johnson & Johnsons 3Q16 Results
11:09AM  Earnings show signs of life
11:04AM  How Did Johnson & Johnsons Pharmaceutical Segment Do in 3Q16?
10:05AM  A Look at Johnson & Johnsons Segment-Wise Performance in 3Q16
08:28AM  Pharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved
08:06AM  Johnson & Johnsons Growth Rate: How Has It Fluctuated?
06:52AM  Health care earnings on parade
Oct-20-16 06:24PM  Johnson & Johnson Reports Growth in 3Q16
05:48PM  Another Health Care Chart Looks Sick
04:10PM  Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2016 PR Newswire
11:43AM  Dependable Johnson & Johnson Needs a Band-Aid
09:30AM  Zacks Market Edge Highlights: Pfizer, Netflix, Baidu, Johnson & Johnson and Domino's Pizza
08:18AM  Post Earnings Coverage as Johnson and Johnson Profit Soars 27 Percent
08:15AM  Post Earnings Coverage as Johnson and Johnson Profit Soars 27 Percent Accesswire
08:09AM  The 3 Biggest Stories From Johnson & Johnson's Third-Quarter Report at Motley Fool
Oct-19-16 08:53PM  Jim Cramer's 'Mad Money' Recap: Politics and Your Portfolio
06:14PM  Cramer: Worried about your money under a Democratic landslide? You should be at CNBC
03:14PM  Abbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View
02:30PM  Incentives make it back into the Florida governors budget at
01:17PM  Short seller Muddy Waters renews claims of St. Jude Medical cyber vulnerabilities at MarketWatch
12:50PM  3 reasons Johnson & Johnson picked Tampa for a global services center (Video) at
11:10AM  FDA to withdraw approval of Lannett's generic ADHD drug at
10:40AM  Johnson & Johnson Opens New Global Services Center In Tampa, Florida PR Newswire
10:35AM  5 Dow Stocks Outperforming Analyst Expectations for 2016 at 24/7 Wall St.
10:11AM  Stock Market News for October 19, 2016
10:05AM  Jim Cramer Remembers the Black Monday Market Crash
10:01AM  Johnson & Johnson :JNJ-US: Earnings Analysis: Q3, 2016 By the Numbers : October 19, 2016
09:54AM  Better Buy: AbbVie Inc. vs. Johnson & Johnson at Motley Fool
09:48AM  Ortho Clinical Diagnostics to Present Data on Automation in Immunohematology, Three Products at 2016 AABB Annual Meeting PR Newswire
08:38AM  Key Takeaways from JNJ's Q3 Call: Remicade, Pipeline, Acquisitions
05:01AM  [$$] Stocks firm as steady dollar helps commodities at Financial Times
12:11AM  [$$] Johnson & Johnson Brushes Off Looming Biosimilar Competition, Posts Solid Results at The Wall Street Journal
Oct-18-16 08:01PM  How to Trade Stocks in the After-Hours
07:35PM  Edited Transcript of JNJ earnings conference call or presentation 18-Oct-16 12:30pm GMT
05:31PM  Hot stocks turn cold
05:28PM  Fortress trades come undone
04:42PM  Netflix and UnitedHealth climb; IBM and Amaya stumble
04:23PM  J&J Tops Q3 Views; Could Buoy Intuitive Surgical, Says Evercore
04:18PM  Intuitive Surgical Q3 EPS Ex Items, Revenue Beat Expectations
04:08PM  Netflix, Goldman Sachs Earnings Push Wall Street Into Rally Mode
02:54PM  US STOCKS-Wall St rallies on earnings optimism
02:39PM  Nasdaq Posts Strong Gains as Netflix Rallies on Earnings Beat
02:19PM  Pfizer's Remicade Rudeness Shouldn't Faze J&J at Bloomberg
02:15PM  Johnson & Johnson: 3 Reasons the Selloff is Overblown at
01:38PM  Stocks Up Nicely; Intuitive Strong Pre-Earnings, Alphabet Breaks Out
01:35PM  J&J shares lose ground on fears of Pfizer's answer to Remicade
01:08PM  US STOCKS-Wall St rallies as S&P seen snapping earnings decline
12:14PM  Competition Is Concerning for Johnson & Johnson
12:13PM  [$$] J&J Brushes Off Looming Biosimilar Competition at The Wall Street Journal
12:12PM  Johnson & Johnson Under Heavy Pressure
12:12PM  J&J Sees No Obstacles From Absence of Tax Reform
11:59AM  Johnson & Johnson tops 3Q Street view but shares decline
11:49AM  Why Johnson & Johnson is Tanking at
11:47AM  3 Proven Ways to Increase Your Retirement Income at Motley Fool
11:40AM  Johnson & Johnson to build new medical device facility in Houston at
11:34AM  US STOCKS-Wall St rallies as strong earnings reports boost optimism
11:14AM  Stocks Are Higher on Strong Corporate Earnings
10:54AM  Why Visa, Johnson and Johnson, Pfizer, and Two Other Stocks Are in Spotlight Today at Insider Monkey
10:45AM  J&J Beats on Q3 Earnings: Should You Buy Healthcare ETFs?
10:42AM  Pharma giants poised to battle over biosimilar medicine at
10:20AM  J&J says stable patients likely to stay with Remicade
10:12AM  Big Q3 Earnings Checklist, Plus Latest CPI
10:10AM  Pharma Boosts Johnson & Johnson Despite Falling Consumer Sales at Motley Fool
10:05AM  J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales
09:59AM  US STOCKS-Wall St rallies on strong corporate earnings reports
09:56AM  J&J says pharma future bright, despite threat to Remicade
09:41AM  Pfizer to Launch Remicade Biosimilar in U.S. in November
09:15AM  Johnson & Johnson Remains Flat Despite Earnings Beat
09:08AM  Johnson & Johnson (JNJ) 'Tracking Higher Expectations,' CFO Caruso Says
08:52AM  US STOCKS-Wall St set to open higher on Goldman, Netflix results
08:36AM  Stock Futures Hold Higher as Consumer Inflation Rises
08:31AM  Pharma giants poised for biosimilar battle at
08:31AM  Johnson & Johnson (JNJ) Beats on Q3 Earnings, Revenues
08:17AM  JOHNSON & JOHNSON Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
08:12AM  J&J Raises Forecast as Profit Beats on Drug Sales
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM